Cystic Fibrosis

CF causes repeat and persistent lung infections that result in frequent exacerbations, sudden severe flare-ups of symptoms, and hospitalizations. Patients endure multiple daily medications, frequent hospitalizations and, ultimately, selected patients have lung transplants.

The quality of life for CF patients is compromised as a result of spending significant time on self-care every day and frequent medical visits and hospitalizations. The US and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.

According to the Cystic Fibrosis Foundation, approximately 40,000 people in the US and an estimated 105,000 people worldwide have been diagnosed with CF across 94 countries.

Ensifentrine has been shown to activate the Cystic Fibrosis Transmembrane Conductance Regulator, which is beneficial in reducing mucous viscosity and improving mucociliary clearance. This suggests ensifentrine has potential as a therapy for CF.